TuHURA Biosciences, Inc. HURA
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $0 | FY ending Dec 31, 2025 | |
|---|---|---|---|
| Operating income | $-19K | +43% | FY ending Jun 30, 2012 |
| Net income | $-30.1M | -39% | FY ending Dec 31, 2025 |
| Earnings per share | $-0.63 | +48% | FY ending Dec 31, 2025 |
| Research & development | $20.5M | +54% | FY ending Dec 31, 2025 |
| Cash from operations | $-27.6M | -88% | FY ending Dec 31, 2025 |
| Capital spending | $76K | +31% | FY ending Dec 31, 2025 |
| Share buybacks | $25K | FY ending Dec 31, 2023 | |
| Cash | $3.6M | -71% | FY ending Dec 31, 2025 |
| Long-term debt | $1,117 | -96% | FY ending Jun 30, 2018 |
| Shareholders' equity | $20.9M | +43% | FY ending Dec 31, 2025 |
| Shares outstanding | 59M | +388% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 0 sales ($0) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
Other insider moves (1): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| James A. BiancoChief Executive Officer, Director | Gift | 150,000 | – | – | May 28, 2026 |
Trades by members of Congress
1 member reported 2 buys and 0 sales since Nov 25, 2024. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Laurel M. Lee R | Bought | $50K–$100K | Jul 13, 2025 | Aug 9, 2025 | Spouse |
| Laurel M. Lee R | Bought | $1,001–$15K | Nov 25, 2024 | Jan 7, 2025 | Spouse |
Latest SEC filings
- News filing: Took on new debt 8-K · Oct 16, 2026
- News filing: Took on new debt 8-K · Sep 24, 2026
- News filing: Took on new debt 8-K · Sep 17, 2026
- News filing: Executive or board change 8-K · Sep 16, 2026
- News filing: Took on new debt 8-K · Sep 4, 2026
- News filing: Took on new debt 8-K · Aug 21, 2026
- News filing: Sold unregistered shares, Shareholder vote results 8-K · Aug 19, 2026
- Quarterly report 10-Q · Aug 14, 2026
- News filing: Quarterly results 8-K · Aug 14, 2026
- News filing: Took on new debt 8-K · Aug 13, 2026
- News filing: Took on new debt 8-K · Jul 29, 2026
- Shareholder meeting proxy DEF 14A · Jul 9, 2026
- News filing: Took on new debt 8-K · Jul 7, 2026
- News filing: Shareholder nominations 8-K · Jun 17, 2026
- News filing: Took on new debt 8-K · May 29, 2026
- Quarterly report 10-Q · May 15, 2026
- News filing: Quarterly results, Public announcement (Reg FD) 8-K · May 15, 2026
- News filing: Signed a major agreement, Took on new debt, Sold unregistered shares, Public announcement (Reg FD) 8-K · Apr 22, 2026
- News filing: Executive or board change, Other news 8-K · Apr 8, 2026
- News filing: Quarterly results 8-K · Apr 1, 2026
- Annual report 10-K · Mar 31, 2026
- News filing: Stock listing notice 8-K · Jan 30, 2026
- News filing: Signed a major agreement, Other news 8-K · Dec 10, 2025
- News filing: Signed a major agreement, Took on new debt 8-K · Dec 5, 2025
- News filing: Public announcement (Reg FD) 8-K · Nov 25, 2025
About TuHURA Biosciences, Inc.
Business description
- Industry
- Pharmaceutical Preparations
- Sector
- Life Sciences
- Headquarters
- Tampa, FL
- Incorporated in
- NV
- Fiscal year ends
- December 31
- Exchange
- Nasdaq
- Filer size
- Non-accelerated filer<br>Smaller reporting company
- Formerly
- Kintara Therapeutics, Inc., DelMar Pharmaceuticals, Inc., Berry Only Inc.
- SEC company number (CIK)
- 1498382
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.